



# COMMITTEE FOR DOCUMENTATION AND DATA MONITORING 2015

**Vassili Niadas, SfEE Secretary General & Committee President**

*Annual General Assembly of SfEE*


*March 20, 2015*

# THE COMMITTEE MEMBERS

- M. Himonas, Z. Vostitsanou, D. Theodoratou, J. Papadonikolaki, SfEE
- A. Angeli, AstraZeneca
- M. Bokaris, Sanofi
- Ch. Martakos, Lilly
- I. Palaka, Amgen
- I. Roubou, Novartis
- R. Siaterli P. Karabela, GSK
- A. Vernadaki, Abbvie
- **And we need more**

## CONCLUSIONS from 2014

- Variability of environment in 2014 and delays in decision-making responsible for outdated information
- Monthly bulletin of financial/market indicators
- Improved distribution of information to the BoD and members
- Improved utilization of material from third-party studies



- Focus around four thematic units:
  - Contribution of medicinal products to Economy, public Finance and Development
  - Developments in pharmaceutical market & economy
  - Measures and impact thereof on welfare and Health
  - Hospitals and other cost centers of Health
- Improve alignment between the Board's strategic needs for documentation and the Committee. Make **swift** decisions.
- Flexibility to order special reports (eg “The state of the pharma industry” for negotiations with the Unions)
- Improved distribution of outcomes to the BoD and SfEE members when such distribution is not legally restricted
- Encourage other Committees to commission their own research, and align with the Documentation Committee

## TWO MESSAGES

### ➤ TO THE BOARD

- **Define** SfEE's needs of documentation with clarity and speediness for better coordination with the Committee's duties

### ➤ TO SfEE MEMBERS

- Encourage your top managers from market access, health economics, public/government affairs, pricing or reimbursement to join the Documentation Committee